Study on Endoscopic Gastric Mucosal Ablation for Class III Obesity Initiated
A clinical trial is investigating the safety and feasibility of Gastric Mucosal Ablation (GMA) for Class III obesity using an endoscopic technique.
Asset / Drug
Drug and asset intelligence for Obesity with 5 indexed intelligence signals across regulatory, clinical, competitive, and market developments.
Peptide Therapy
No catalysts indexed for this entity yet.
No catalysts indexed for this entity yet.
No related entities indexed yet.
Newsletter
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.